Press release content from PR Newswire. The AP news staff was not involved in its creation.
Allen Institute For Cell Science Announces Leadership Changes
December 11, 2020 GMT
SEATTLE, Wash., Dec. 11, 2020 /PRNewswire/ The Allen Institute for Cell Science, a division of the Allen Institute, announced today that Ruwanthi (Ru) Gunawardane, Ph.D., has been named Executive Director, effective January 9, 2021, providing executive direction and leadership. Susanne Rafelski, Ph.D., Deputy Director, will manage and lead the scientific research. Rick Horwitz, Ph.D., will assume the role of the Institute’s Senior Advisor and Inaugural Executive Director, Emeritus, and will be active in the Institute’s dissemination and alliance efforts.
COVID-19 infection may also affect the central nervous system, cause neurological disorders
COVID-19 is known primarily as a respiratory disease, with symptoms that include cough, shortness of breath, and, in severe cases, acute respiratory distress syndrome and pneumonia. Now, researchers from Cleveland Clinic s Department of Biomedical Engineering note in a recent review that infection with the coronavirus may also affect the central nervous system and cause corresponding neurological disorders, including ischemic stroke, encephalitis, encephalopathy and epileptic seizures.
According to the review published in
Cells and authored by Chaitali Ghosh, PhD, and Aneesha Achar the symptoms of COVID-19-related neurological manifestations include dizziness, headache, a loss of consciousness and ataxia (loss of balance and muscle control).
Researchers use AI platform to identify best combination of available therapies against COVID-19.
A team of researchers from the National University of Singapore (NUS) has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.
Their results showed that the optimal drug therapy was a combination of the drugs remdesivir, ritonavir, and lopinavir at specific doses.
Remdesivir is a broad antiviral medication that was recently approved by the United States Food and Drug Administration as a treatment for COVID-19. The team showed that a combination of remdesivir with ritonavir and lopinavir led to a treatment that was 6.5 times more effective than the limited effects of remdesivir alone.
Using AI to find optimal combination of available therapies against SARS-CoV-2
A team of researchers from the National University of Singapore (NUS) has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19. Their results showed that the optimal drug therapy was a combination of the drugs remdesivir, ritonavir, and lopinavir at specific doses.
Remdesivir is a broad antiviral medication that was recently approved by the United States Food and Drug Administration as a treatment for COVID-19. The team showed that a combination of remdesivir with ritonavir and lopinavir led to a treatment that was 6.5 times more effective than the limited effects of remdesivir alone.
Singapore uses AI to find best combination therapies for COVID-19 biospectrumasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumasia.com Daily Mail and Mail on Sunday newspapers.